We thank Erdol and colleagues for their comments on our study evaluating serum adropin levels among patients with nonalcoholic fatty liver disease [1]. Their point on the association of levels of adropin with the bioavailability of nitric oxide (NO), an important factor in endothelial dysfunction and atherosclerosis, is very important. In our study, we also discussed that endothelial NO synthetase expression has been reported to be induced by adropin, resulting in a direct association between NO and adropin levels [2]. Ertem et al. [3] showed that increased levels of serum adropin in patients with acute coronary syndrome is also important indicating the role of adropin in clinical practice. In our study, we excluded patients with a history of coronary artery disease. Moreover, we also excluded patients with diabetes mellitus, hypertension, or obesity to eliminate the effects of these chronic diseases on endothelial dysfunction and atherosclerosis. We suggest that decreased levels of adropin in patients with nonalcoholic fatty liver disease should be studied further as a possible predictor of coronary artery disease.
© 2019 The Author(s) Published by S. Karger AG, Basel
2019
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
